Literature DB >> 1522481

A computationally efficient approach for the design of population pharmacokinetic studies.

J Wang1, L Endrenyi.   

Abstract

A computationally efficient procedure was devised for designing experiments in which population pharmacokinetic parameters are estimated. The method, referred to as the large-sample approach, evaluates the variances of parameter estimates for a population pharmacostatistical model. The procedure utilizes the NONMEM program and requires a single simulation that assumes many, say 1000, subjects. The approach reduced CPU time by about a factor of 50 when compared with the evaluation of the same variances by the direct simulation of experiments. The large-sample and simulation approaches yielded generally similar values for the variances of parameter estimates. The variances calculated by the large-sample approach were, in the case of a simple model, close to the expected variances. The proposed method identified correctly the imprecise parameter estimates but somewhat underestimated their variances.

Mesh:

Year:  1992        PMID: 1522481     DOI: 10.1007/bf01062528

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  5 in total

1.  Experimental design and efficient parameter estimation in population pharmacokinetics.

Authors:  M K al-Banna; A W Kelman; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

2.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1983-06

4.  Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-10

5.  Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis.

Authors:  Y Hashimoto; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1991-06
  5 in total
  8 in total

1.  Robust optimal design for the estimation of hyperparameters in population pharmacokinetics.

Authors:  M Tod; F Mentré; Y Merlé; A Mallet
Journal:  J Pharmacokinet Biopharm       Date:  1998-12

2.  Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design.

Authors:  Y Merlé; M Tod
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-08       Impact factor: 2.745

3.  Optimization of individual and population designs using Splus.

Authors:  Sylvie Retout; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

Review 4.  A pragmatic approach to the design of population pharmacokinetic studies.

Authors:  Amit Roy; Ene I Ette
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

5.  Development of limited sampling strategies for characteristics of a pharmacokinetic profile.

Authors:  W M Sallas
Journal:  J Pharmacokinet Biopharm       Date:  1995-10

Review 6.  Facilitation of drug evaluation in children by population methods and modelling.

Authors:  Michel Tod; Vincent Jullien; Gérard Pons
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study.

Authors:  Hiwot Hiruy; Zoe Rogers; Chris Mbowane; John Adamson; Lihle Ngotho; Farina Karim; Tawanda Gumbo; William Bishai; Prakash Jeena
Journal:  J Antimicrob Chemother       Date:  2014-12-11       Impact factor: 5.790

8.  The Non-Linear Child: Ontogeny, Isoniazid Concentration, and NAT2 Genotype Modulate Enzyme Reaction Kinetics and Metabolism.

Authors:  Zoe Rogers; Hiwot Hiruy; Jotam G Pasipanodya; Chris Mbowane; John Adamson; Lihle Ngotho; Farina Karim; Prakash Jeena; William Bishai; Tawanda Gumbo
Journal:  EBioMedicine       Date:  2016-07-27       Impact factor: 8.143

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.